Oct 23 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA STRENGTHENS AND EXPANDS ITS ONCOLOGY DEVELOPMENT COLLABORATION WITH ASTRAZENECA.INNATE PHARMA ACQUIRES US AND EU RIGHTS TO COMMERCIALIZE LUMOXITI TO BECOME A FULLY-INTEGRATED ONCOLOGY-FOCUSED BIOTECH.ASTRAZENECA OBTAINS FULL ONCOLOGY RIGHTS TO MONALIZUMAB.ASTRAZENECA GAINS ACCESS TO INNATE PHARMA'S ANTI-CD39 MONOCLONAL ANTIBODY, IPH5201, PLUS FOUR ADDITIONAL IMMUNO-ONCOLOGY MOLECULES.ASTRAZENECA TO PURCHASE NEWLY-ISSUED EQUITY STAKE OF 9.8% IN INNATE PHARMA.
Full Article
Oct 23 (Reuters) - AstraZeneca Plc ::ASTRAZENECA EXPANDS ONCOLOGY DEVELOPMENT AND COMMERCIALISATION COLLABORATION WITH INNATE PHARMA.WILL OBTAIN FULL ONCOLOGY RIGHTS TO HUMANISED ANTI-NKG2A ANTIBODY, MONALIZUMAB.ALSO GAINS OPTION RIGHTS TO IPH5201, ANTIBODY TARGETING CD39, & FOUR PRECLINICAL MOLECULES FROM INNATE'S PIPELINE.INNATE WILL PAY ASTRAZENECA $50 MILLION UPFRONT FOR LUMOXITI.INNATE TO PAY $25 MILLION FOR CERTAIN FUTURE MILESTONES FOR INTELLECTUAL PROPERTY AND CLINICAL AND MANUFACTURING DEVELOPMENT OF LUMOXITI.
Full Article
Oct 22 (Reuters) - INNATE PHARMA ::INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER.CONFIRMATION OF PREVIOUSLY REPORTED RESPONSE RATE AND NEW DATA ON DURABILITY OF RESPONSE REINFORCES THE POTENTIAL ANTI-TUMOR ACTIVITY OF THE MONALIZUMAB CETUXIMAB COMBINATION.CLINICAL PROGRAM ADVANCES WITH EXPANSION COHORT IN PATIENTS PREVIOUSLY TREATED WITH PD-1/L1 THERAPIES.IN STUDY EVALUATING COMBINATION OF MONALIZUMAB AND CETUXIMAB OVERALL RESPONSE RATE WAS 27.5% (BY RECIST) INCLUDING 1 CONFIRMED COMPLETE RESPONSE (2.5%) AND 10 PARTIAL RESPONSES (25%).DISEASE CONTROL RATE AT 24 WEEKS (DCR) WAS 35%.MEDIAN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) REACHED 5.0 AND 10.3 MONTHS, RESPECTIVELY.IN ADDITION, THERE WERE 3 (18%) RESPONDERS AMONG 17 PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH PD-1/L1 ANTIBODIES.AMONG 40 PATIENTS ENROLLED IN COHORT EXPANSION, SAFETY FINDINGS WERE CONSISTENT WITH PREVIOUSLY PRESENTED DATA AT AACR 2017 AND 2018, WITH NO ADDITIONAL SAFETY CONCERNS COMPARED TO MONALIZUMAB OR CETUXIMAB GIVEN ALONE.
Full Article
April 17 (Reuters) - INNATE PHARMA SA ::PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN.8 PARTIAL RESPONSES IN 26 PATIENTS EVALUABLE FOR EFFICACY IN MONALIZUMAB PHASE I/II TRIAL.NUMBER OF RESPONSES NEEDED TO DECLARE TRIAL RESULT POSITIVE IS REACHED.COMBINATION WAS WELL TOLERATED, WITHOUT POTENTIATING CETUXIMAB-RELATED SIDE EFFECTS.TOTAL ENROLLMENT OF 40 PATIENTS NOW COMPLETED.
Full Article
Jan 31 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD.
Full Article
Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.
Full Article
Nov 22 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB.LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS.COMBINATION OF NIVOLUMAB PLUS LIRILUMAB IN EXTENDED POPULATION OF PATIENTS WITH SCCHN DID NOT PROVIDE CLEAR EVIDENCE OF BENEFIT TO PATIENTS OR OBVIOUS DEVELOPMENT PATH.ON COMBINATION OF NIVOLUMAB PLUS LIRILUMAB: DISCUSSIONS ARE ONGOING REGARDING NEXT STEPS.AN UPDATE IS PLANNED FOR EARLY 2018.
Full Article
Nov 15 (Reuters) - INNATE PHARMA SA ::Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO.9 MONTH REVENUE EUR 27.9 MILLION VERSUS EUR 27.9 MILLION YEAR AGO.CASH POSITION AT SEPT 30 EUR 195.7 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.
Full Article
Sept 18 (Reuters) - INNATE PHARMA SA ::CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS(1) FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017.A NET LOSS FOR FIRST HALF OF 2017 AMOUNTING TO EUR 23.4M (EUR 3.2M FOR FIRST HALF OF 2016)..H1 REVENUE EUR 21.3 MILLION VERSUS EUR 20.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 18.2 MILLION VERSUS LOSS OF EUR 2.9 MILLION YEAR AGO.
Full Article
Earnings vs. 
Estimates